Tag Archives: Biotech VC

Over 200 GLP1 obesity programs are in development today.  More than 300 PD1/PDL1 cancer programs exist.  Greater than 150 programs target each of CD19 and KRAS. Therapeutic crowding has ratcheted up the competitive intensity in biotech to new levels. While

Biotech feels like it’s got some wind in its sails here at the start of 2024, with positive sentiments from the JPM conference. Indeed, the public equity markets feeling somewhat buoyant for the first time in ages. With the close

Venture capital has been on a good run over the past few years across a range of sectors; even with recent slowdown relative to 2014-2015, venture-backed investments remain above historic averages.  In fact, the first three quarters of 2016 alone